ALFA Finder| Management target | Revenue 18.0% FY32 |
|---|
| Revenue growth | 20% YoY growth to ₹946 Cr driven by animal health formulations. |
|---|---|
| Margins | EBITDA margins expanded 540 bps YoY to 21.6% via integration. |
| Order book | API orders rebounding after June lull caused by market volatility. |
| Demand visibility | Strong visibility in companion animal and human oncology API markets. |
| Management confidence | Highly confident, emphasizing consistent results and a strengthened debt-free balance sheet. |
Growth
Revenue grew 19.5% YoY to ₹946 Cr; EBITDA increased 59.2% led by operational efficiency and backward integration.
Outlook
Targeting $1 billion revenue by FY32 with 18% CAGR; focused on companion animal and complex oncology APIs.
Risks
Near-term API pricing volatility and raw material cost fluctuations impacted sequential growth in the API segment.
Last quarter's promises, checked
Delivered
- Guided 13% p.a. revenue growth → delivered 20% (= BEAT)
- Guided 60% p.a. EBITDA growth → delivered 59.2% (= BEAT)
- Guided FY26 revenue ₹34,203 MN → delivered ₹37,840 MN annualized (= BEAT)
Partly delivered
- Guided EBITDA margin expansion → delivered 21.6% but API segment volatility persists (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹255.33
- Market cap
- ₹11,285 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 65.9×Sector 43.8×
- Promoter holding
- 49.24%-12.07% QoQ
- FII holding
- 2.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 228,408 shares under two employee stock option schemes. Paid-up capital rose to 44,19,91,958 shares of Rs.2 each.
Viyash Scientific Board Meeting Date
Viyash Scientific will hold a board meeting on 13 November 2026 to consider unaudited quarterly and half-yearly results. The trading window remains closed until 15 November 2026.
Viyash Scientific Merger & Restructuring Worth ₹3.8 Cr
Viyash's step-down subsidiary Alivira Vietnam was incorporated on 30 October 2026, with investment up to USD 400,000. It will distribute animal health products and APIs in Vietnam.
- Value
- ₹3.80 Cr
Viyash Scientific Management Change
Viyash Scientific Limited has appointed Dr. Mallikharjuna Rao Nagineni as Senior Vice President, Human Resources, succeeding the retiring Mr. Prasad Lad.
Viyash Scientific Capital Structure Change
White Oak Capital Management Consultants LLP disclosed the sale of 8,747,392 equity shares of Viyash Scientific Ltd, reducing its stake in the open market.
Viyash Scientific Other Announcement
Viyash Scientific Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.